Clinical Trial

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.
Protocol Amendment History 2 changes
notable Trial sites expanded: 2 -> 5 locations 2026-05-27
critical Recruitment opened 2026-04-16
Trial Details
NCT Number NCT07288333
Lead Sponsor Neurocrine Biosciences
Conditions Schizophrenia
Enrollment 120 participants
Start Date 2026-02-16
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-22